Successful Rechallenge of Trastuzumab Deruxtecan Following Early Detection of ILD in a Patient with Non-small Cell Lung Carcinoma Harboring HER2 Exon 20 Insertion.

We herein report the case of a 78-year-old woman with non-small cell lung carcinoma (NSCLC) harboring a HER2 exon 20 insertion, who developed grade 1 trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) during third-line therapy. Or…

Preview only. Read the full abstract at the source